How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/soft-or-connective-tissue-sarcoma.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-11 · How we verify

Soft or Connective Tissue Sarcoma — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Soft or Connective Tissue Sarcoma (disease) competitive landscape: 8 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

8 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Soft or Connective Tissue Sarcoma, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Yondelis	TRABECTEDIN	Janssen Prods	Alkylating Drug [EPC]	Proto-oncogene tyrosine-protein kinase Src	2015-01-01
Liposomal Doxorubicin	liposomal-doxorubicin	Pfizer	doxorubicin	72 kDa type IV collagenase	1974-01-01
Doxorubicin Hydrochloride	doxorubicin	Pfizer	Anthracycline Topoisomerase Inhibitor	Aurora kinase A	1974-01-01
Adriamycin	Adriamycin	Johann Wolfgang Goethe University Hospital		Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase
Yondelis	Yondelis	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.		Proto-oncogene tyrosine-protein kinase Src, Nuclear receptor subfamily 1 group I member 2
Hydroxydaunomycin	Hydroxydaunomycin	Weill Medical College of Cornell University		Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase
Hydroxydaunorubicin	Hydroxydaunorubicin	University of Colorado, Denver		Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase
adriacin	adriacin	Chipscreen Biosciences, Ltd.		Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Pfizer · 2 drugs in Soft or Connective Tissue Sarcoma
Janssen Prods · 1 drug in Soft or Connective Tissue Sarcoma
Johann Wolfgang Goethe University Hospital · 1 drug in Soft or Connective Tissue Sarcoma
Chipscreen Biosciences, Ltd. · 1 drug in Soft or Connective Tissue Sarcoma
University of Colorado, Denver · 1 drug in Soft or Connective Tissue Sarcoma
Weill Medical College of Cornell University · 1 drug in Soft or Connective Tissue Sarcoma
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · 1 drug in Soft or Connective Tissue Sarcoma

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Soft or Connective Tissue Sarcoma:

Cite this brief

Drug Landscape (2026). Soft or Connective Tissue Sarcoma — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/soft-or-connective-tissue-sarcoma. Accessed 2026-06-11.

Soft or Connective Tissue Sarcoma full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing